Welcome to our dedicated page for CERo Therapeutics news (Ticker: CERO), a resource for investors and traders seeking the latest updates and insights on CERo Therapeutics stock.
CERo Therapeutics Holdings, Inc. develops cellular immunotherapy candidates for cancer using engineered T cells that employ phagocytic mechanisms. Company news centers on its CER-T platform, the lead product candidate CER-1236, and clinical updates from the CERTAIN-T Phase 1 trial in hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis.
Recurring updates also address safety monitoring, pharmacokinetic and pharmacodynamic observations, dose-escalation cohorts, scientific presentations, board composition, financing activity, and trading or listing-status developments for CERO common stock and warrants.
CERo Therapeutics (Nasdaq: CERO) presented data on their lead compound, CER-1236, at the Global Cell & Gene Therapy Summit 2024. The data reveals that TIM-4-L, a target for engineered T cell therapy, is prevalent in acute myeloid leukemia (AML) but absent in healthy tissue. CER-1236 demonstrated strong cytotoxicity against TP53 mutant AML in both in vitro and in vivo studies without causing adverse effects in healthy tissues, even at high doses. The company anticipates the start of initial human trials focused on AML pending IND clearance.
CERo Therapeutics has completed the necessary IND-enabling activities for its lead compound, CER-1236. The successful manufacturing runs meet the required safety and efficacy standards for drug administration in clinical trials. This accomplishment marks the final technical step needed before submitting the Investigational New Drug (IND) Application to the FDA. The company anticipates a near-term filing of the IND to enable the commencement of Phase 1 human trials. Chairman and CEO Brian G. Atwood emphasized this milestone as important for advancing CERo's therapeutic pipeline and acknowledged the team's efforts. Further updates on the IND filing are expected soon.
CERo Therapeutics has successfully completed toxicology studies for its lead compound, CER-1236, an important step toward submitting an Investigational New Drug (IND) application to the FDA. The South San Francisco-based company focuses on innovative immunotherapy, specifically engineered T cell therapeutics. According to CERo's Chairman and CEO, Brian G. Atwood, the company is now nearing readiness for FDA submission to begin Phase 1 human trials. The next steps include completing compliant manufacturing procedures and other final IND-enabling studies. The company expects to finalize its IND package in the coming weeks and will keep shareholders updated on progress.
CERo Therapeutics, a South San Francisco-based immunotherapy company listed on Nasdaq under the ticker CERO, has provided a corporate update. After merging with SPAC Phoenix Biotech Acquisition in June 2023 and completing the de-SPAC process in February 2024, CERo is now positioned as an operating Nasdaq-traded entity. Key activities include completion of preclinical milestones and preparation for clinical trials with their lead candidate CER-1236, aimed at treating Acute Myeloid Leukemia (AML). March 2024 saw the publication of a paper in Clinical Cancer Research detailing CER-1236's efficacy. The company is finalizing Investigational New Drug (IND) application requirements for the FDA and plans to update shareholders via investor conferences and additional publications.
CERo Therapeutics, Inc. presents encouraging preclinical data for AML on CER-1236 at Stanford Drug Discovery Symposium, highlighting tumor elimination and manufacturing attributes. The poster outlines the successful elimination of adverse-risk AML cell lines by CER-1236 engineered T cells with low off-tumor toxicity to HSPCs. Additionally, the company demonstrates high yields of CER-1236 drug product with favorable memory and immunophenotypic profiles.
Summary not available.
Summary not available.